Irvine, CA-Visiogen Inc. says it has received FDA approval to expand its phase III U.S. clinical trial for its dual-optic accommodating IOL (Synchrony).
ChatGPT may have a future use in glaucoma
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
Therapeutic in development to take on diabetic macular edema
Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention
Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410
Stress resilience–enhancing drugs: New class of small molecules holds promise